These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23965719)

  • 1. [Therapies in multiple sclerosis].
    Kesselring J
    Praxis (Bern 1994); 2013 Aug; 102(17):1061-7. PubMed ID: 23965719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multiple sclerosis: can therapy delay ongoing disability?].
    Havla J; Pellkofer HL; Hohlfeld R; Kümpfel T
    MMW Fortschr Med; 2011 Apr; 153(14):63-6. PubMed ID: 21966873
    [No Abstract]   [Full Text] [Related]  

  • 3. A new treatment era in multiple sclerosis: clinical applications of new concepts.
    Edan G; Leray E
    J Neurol Sci; 2011 Jul; 306(1-2):170-2. PubMed ID: 20951999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic management of multiple sclerosis.
    Blasier MG
    Urol Nurs; 2008 Jun; 28(3):217-9. PubMed ID: 18605517
    [No Abstract]   [Full Text] [Related]  

  • 5. A practical guide to pediatric multiple sclerosis.
    Huppke P; Gärtner J
    Neuropediatrics; 2010 Aug; 41(4):157-62. PubMed ID: 21086219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

  • 7. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multiple sclerosis--what should be done?].
    Kesselring J
    Ther Umsch; 1993 Nov; 50(11):766-70. PubMed ID: 7514811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
    Orthmann-Murphy JL; Calabresi PA
    Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update: treatment of multiple sclerosis].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2009 Mar; 151(13):70-2. PubMed ID: 19504824
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 13. [Multiple sclerosis: new treatment options].
    Marziniak M
    MMW Fortschr Med; 2014 Mar; 156 Spec No 1(1):69-73; quiz 74. PubMed ID: 24930351
    [No Abstract]   [Full Text] [Related]  

  • 14. [EDMUS--a new European databank for multiple sclerosis. A brief introduction of ongoing and planned multicenter studies within the scope of the "European Concentrated Action for Multiple Sclerosis"].
    Flachenecker P; Hartung HP
    Nervenarzt; 1996 Apr; 67(4):277-82. PubMed ID: 8684505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
    Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract]   [Full Text] [Related]  

  • 16. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta in multiple sclerosis: how much BENEFIT?
    Pittock SJ
    Lancet; 2007 Aug; 370(9585):363-4. PubMed ID: 17678997
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N; Stepień A; Chalimoniuk M
    Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurorehabilitation of multiple sclerosis].
    Cáceres FJ
    Rev Neurol; 2000 Sep 1-15; 31(5):477-81. PubMed ID: 11027102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.